Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Rabin Medical Center Identifier:
First received: January 2, 2007
Last updated: January 3, 2007
Last verified: December 2006
The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Condition Intervention Phase
Drug: AS101
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Resource links provided by NLM:

Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • hair density

Secondary Outcome Measures:
  • Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,
  • Self-administered satisfaction questionnaire

Estimated Enrollment: 40

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women in menopause, over 50 years of age.
  • Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion Criteria:

  • Women treated with chronic medications.
  • Use of Minoxidil within 3 months prior to entering study.
  • Women who have underwent hair transplantation.
  • Use of drugs with androgenic or anti-androgenic effects.
  • Any other type of hair loss.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00418249

Contact: Danny Ben Amitai, MD 972-3-9253770
Contact: Raziel Lurie, MD

Not yet recruiting
Tel Aviv, Israel
Contact: Danny Ben Amitai    972-3-9253770      
Sponsors and Collaborators
Rabin Medical Center
Principal Investigator: Danny Ben-Amitai, M.D. Rabin Medical Center
  More Information Identifier: NCT00418249     History of Changes
Other Study ID Numbers: #69 REV 00 
Study First Received: January 2, 2007
Last Updated: January 3, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Rabin Medical Center:
Androgenetic Alopecia
Telogen effluvium
Chronic telogen effluvium
Female Androgenetic Alopecia (FAGA)

Additional relevant MeSH terms:
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Ammonium trichloro(dioxoethylene-O,O'-)tellurate
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Radiation-Protective Agents
Protective Agents processed this record on October 25, 2016